Keywords: Bayer, Algeta, Alpharadin, Prostate cancer, USA, FDA, fast-track
US FDA fast-tracks Bayer and Algeta’s prostate drug Alpharadin
Article | 23 August 2011
Germany’s Bayer (BAY: DE) said this morning that its investigational compound Alpharadin (radium-223 chloride), licensed from Norwegian cancer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
